Reports from Dr. Catalona’s Follow-up Studies

Categories: Winter 2002

Comparing Treatments

Radical prostatectomy provides a higher 7-year PSA progression-free rate than other treatments for localized prostate cancer.

A member of Dr. Catalona’s research team in St. Louis, Julie Krygiel, reported preliminary results at the American Urological Association (AUA) on a study of 2,477 men from Dr. Catalona’s PSA Follow-up Study comparing various treatments for localized prostate cancer: radical prostatectomy, radiotherapy, hormonal therapy and observation (“watchful waiting”).

The PSA Follow-up Study was conducted on patients three or more years after they had been treated and used post-treatment PSA measurements to determine whether there was cancer progression.

The calculated 7-year progression-free rates varied greatly between treatment groups. Radical prostatectomy was the most effective with an 82% 7-year progression-free rate.

Radiotherapy, another potentially curative treatment, produced a rate of 67% and then hormone therapy, which only slows progression, had 72% progression-free rate.

The lowest progression-free rate was in patients who elected watchful waiting, with only with 35% showing no progression.

Effects of Screening on Survival

More evidence is suggesting that screening may improve outcomes of prostate cancer patients by increasing detection of organ-confined disease and decreasing prostate cancer mortality rates.

A member of Dr. Catalona’s research team in St. Louis, Kimberley Roehl, presented these results at a recent AUA conference.

Dr. Catalona treated all the patients in the study, but 443 came from a PSA screening program and 2,413 came as physician-referred patients.

The screening study recommended biopsy for PSA greater than 4 before 1995 and greater than 2.5 after 1995, or after a suspicious digital rectal exam (DRE).

Overall, the screened population had a 5% better PSA progression-free, total recurrence rate and organ-confined disease than the referred patients.

The goal of screening is to detect favorable prostate cancers – those with a Gleason score of 5-6, a low PSA, organ-confined tumor and low tumor volume – and the more favorable results of those screened were associated with lower PSA, Gleason grade and pathologic stage which occur with effective and regularly scheduled screening.

Subscribe to Quest

Dr. Catalona Pic With Donate Now Button